Bowen Liu

Investing Partner, Andreessen Horowitz · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

investorscientistengineera16z.com/bio-health ↗

Bowen Liu is an Investing Partner on the Bio + Health team at Andreessen Horowitz. He previously conducted machine learning and cheminformatics research at insitro and completed his Ph.D. at Stanford University.

5statements → 4claims → 0claims resolved → 3.4/5average certainty → 2/5average debate potential →

4 not checkable as stated how the 4 claims stand · each chip opens the sources

4 assertions · 1 insight · every statement was checked. The predictions and assertions are the 4 claims: statements the public record can support or contradict. 0 are resolved, and 4 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

What they said5 Episodes1

Everything Bowen Liu said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Not checkable as stated

Liu: Protein structure prediction is essentially solved for many common proteins

“In the past, like, four or five years, this problem of protein structure prediction went from, you know, something that was, you know, quite far away from being solved, to now you could argue that, It's pretty much been solved for a lot of, like, common kind o…”

Bowen Liu Oct 3, 2024 ▶ 8:20 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Insight

Liu: Generative AI in science makes validation much harder than idea generation

“In science, you know, it's actually the inverse. Like, it's actually, it's probably easier to generate ideas, but way harder to validate.”

Bowen Liu Oct 3, 2024 ▶ 12:52 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Assertion Not checkable as stated

Bowen Liu calls labeled data scarcity the core bottleneck in scientific AI

“Yeah, I think you touched on, like, probably the core problem of, like, you know, ML applied to science. While we have a lot of, like, unlabeled data, like, there's just not that much label data out there. And a lot of it is because, like, it's very experiment…”

Bowen Liu Oct 3, 2024 ▶ 7:09 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Assertion Not checkable as stated

Bowen Liu: Small Molecules Currently Lack Self-Supervised Learning Frameworks

“Because like with protein sequences and biological sequences, like you can actually do self-supervised learning, right? Because there is this like complicated generative process with like evolutionary pressure that you can learn from. There's no equivalent for…”

Bowen Liu Oct 3, 2024 ▶ 18:05 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Assertion Not checkable as stated

Liu: 100 active compounds is a drug candidate but tiny for ML

“Usually in a drug discovery project, you know, if you have a hundred actives, you should be close to a drug, but a hundred data points is, like, tiny for machine learning, right?”

Bowen Liu Oct 3, 2024 ▶ 7:28 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

Appearances (1)

Episode	Date	Speaking time
AI at the Intersection of Bio \| Vijay Pande, Surya Ganguli & Bowen Liu	Oct 3, 2024	7m

Bowen Liu

Appearances (1)

Turn any episode into a week of clips.